- Visibility 82 Views
- Downloads 9 Downloads
- DOI 10.18231/j.achr.2023.064
-
CrossMark
- Citation
Metastatic ovarian high grade serous carcinoma with intestinal and omental deposits and marked clinicopathological treatment response in right ovary: A rare case report
Introduction
Epithelial ovarian cancer has a high metastatic potential and is the leading cause of death from gynaecologic malignancy.[1], [2] Most patients with ovarian cancer presents after the tumor has metastasized to the peritoneum outside the pelvis such as the omentum, small intestine, mesentery, retroperitoneal lymph nodes or to distant organs such as liver, bone, spleen, lung and lymph nodes outside the abdominal cavity. [3] Due to this, a complete resection in debulking surgery is difficult for patients with advanced ovarian cancer to undergo. [4] Furthermore, many of the patients initially respond to the chemotherapy, however chemoresistant residual tumors can survive in metastatic sites. [5], [6]
With regard to the metastatic pathway, it has been found that ovarian cancer cells preferentially metastasize to the omentum via direct dissemination instead of via hematogenous routes because of lack of anatomical barriers around the primary lesion of ovarian cancer in the abdominal cavity. [4]
Although omentum is primarily an adipose tissue, it also contain clusters of leukocytes called ‘milky spots’ consisting of T and B lymphocytes, macrophages and dendritic cells that contribute to peritoneal immunity by collecting antigens and pathogens and promoting immune response. [7] Crucially, the omentum collects metastasising tumor cells and supports tumor growth by immunological and metabolic mechanisms. [8], [9]
Case Report
A 65 years old female, Parity 4 with 3 spontaneous abortions presented to Gynaecologic outpatient department with complaints of postmenopausal bleeding for 3months. There was no history of fever, cough and weight loss. There was no history of hypertension, tuberculosis and diabetes mellitus. There was no history of endometrial carcinoma. No other significant past medical or surgical history was known. None of the family members had similar complaints. Consent was obtained from the patient and a general physical examination was performed.
On physical examination, patient was pale. She was found to have mild distension of the abdomen. Her abdomen was non tender to palpation with normal bowel sounds. There was no hepatomegaly and splenomegaly. Pelvic examination revealed a painless non mobile right adnexal mass.
Investigations showed microcytic hypochromic anemia with haemoglobin of 7.0 g% with leucocyte count of 14500cells/mm3. Liver function test was normal. Contrast Enhanced Magnetic Resonance Imaging (CE-MRI) showed a hetrogenous lobulated lesion enhancing lesion in right adnexa with non-visualization of right ovary, separately appearing hypointense on T1 and hetrogenously on T2, of size 4.2×6.0×4.2cm. Anterosuperiorly the lesion was abutting small bowel loops and sigmoid colon with focally indistinct fat planes. Also few small hypointense lesions appearing T1/T2 hypointense relative to myometrium (?Intramural fibroid of size 5×6mm) were seen.
Biopsy showed solid sheets and few papillary structure having markedly pleomorphic cells with high nucleocytoplasmic ratio, hyperchromatic nuclei with scant to moderate eosinophilic cytoplasm. Frequent mitosis were seen.The patient was diagnosed as a case of high grade serous carcinoma of right ovary. She then received 6 cycles of chemotherapy at an interval of 21 days comprising of combination of Paclitaxel in a dose of 165mg/m2 and Cisplatin in a dose of 50mg/m2.
After 4 months of the presenting complaints she developed gradual onset of abdominal discomfort and backache. She also complained of yellowish discharge per vaginum. A repeat CE-MRI showed heterogeneity in the right adnexa with no markedly appreciable abnormal foci in the right ovary and ascending colon. Left ovary appeared atrophied. No significant pelvic lymphadenopathy was seen.
Following which, a transabdominal hysterectomy with bilateral salpingo-oophorectomy, Right hemicolectomy with omentectomy was performed. On gross examination, uterus and cervix measured 5.5×4.5×1.5cm. Right ovary – 2×1.5cm, right fallopian tube – 4cm, left ovary – 1×0.5cm, left fallopian tube - 4.5cm. There was also a fatty tissue piece (?omentum) measuring 10×5×4cm which on serial sectioning, showed multiple, firm white areas (?tumor areas).


On immunohistochemistry, CK 7 was found to be positive in the tumor cells in the intestine and omentum ([Figure 3])

Microscopic examination of right ovary revealed complete collagenization without any evidence of atypical epithelial cells. Blood vessels were thickened and congested. Stroma was thickly collagenized with widespread areas of hyaline degeneration and focal collection of theca cells and corpus luteum. No evidence of any atypical cells were seen. However, section from the intestine and omentum shows sheets of atypical cells along with mononucleated, binucleated and multinucleated tumor cells scattered in omentum admixed with omental fat, congested blood vessels and lymphocytic infiltration with areas of haemorrhage and necrosis ([Figure 1], [Figure 2]).
On the basis of history, clinical examination and investigations, the patient was diagnosed as a case of metastatic High Grade Serous Carcinoma with marked treatment response in right ovary (yPT3aNx) Stage IV with intestinal and omental metastasis. Post operatively patient was given 3 cycles of chemotherapy consisting of paclitaxel in a dose of 50mg/m2. Our patient was followed up for 6 months with no evidence of recurrence.
Discussion
High grade serous ovarian cancer is the most prevalent as well as the most fatal type of ovarian cancer accounting for approximately 30.0-60.0% of the cases and causing 70.0-80.0% of the mortalities. [10] Due to lack of screening methods and the nonspecific symptoms associated with HGSC, the majority of the women are diagnosed only after extensive metastasis has occurred.[11] Treatment includes combination of surgical debulking and platinum-based chemotherapy, however many patients suffer from recurrences and the overall survival is 46.0%.[12]
HGSC is a heterogenous disease because cases have a diversity of clinical features, therapeutic responses and prognosis.[13] Analysis of gene expression microarray from the cancer genome atlas project revealed that HGSC could be classified as one of the four gene expression subtypes: immunoreactive, differentiated, proliferative or mesenchymal. These subclassifications display distinct prognosis and sensitivities to chemotherapy.[14], [15] Of these histopathological classification the mesenchymal type which is defined by a remarkable desmoplastic reaction has the worst prognosis and the immunoreactive, which is defined by lymphocytes surrounding and infiltrating the malignant tissue has the most favourable prognosis.[13] Previous studies suggested that metastatic ovarian cancer cells acquire chemoresistance by a reciprocal interaction with stromal cells in the omentum, which subsequently leads to unfavourable outcome.[4]
During ovarian cancer metastatic spread, the omentum is one of the most preferred sites of metastasis and frequently forms a large mass known as ‘omental cake’.[4] The immunomodulatory functions and adipose rich composition of the omentum are thought to create a tumor promoting niche that encourages an inflammatory and proangiogenic microenvironment.[8] Omental adipocytes express high levels of IL-6, TIMP1 and adiponectin which can recruit tumor cells.[16]
Omental metastasis is an independent prognostic factor and is associated with increased chemoresistance in stage III-IV ovarian cancer patients.[4] In a study, patients with a poor response to chemotherapy for omental metastatic tumors had significantly worse survival outcomes than patients with good response to chemotherapy in advanced stage ovarian cancer.[4]
In the current clinical guidelines, omentectomy is included in the standard surgical procedure for all cases of ovarian cancer for assessing adequate surgical staging.[17], [18], [19], [20] However, it has been not clear whether excising the omentum has therapeutic significance, despite the recommendation for undergoing omentectomy.[21]
Our patient was diagnosed as a case of high grade serous carcinoma of right ovary which metastasized to the omentum. The patient had received 6 cycles of chemotherapy prior to surgery. Patient then underwent transabdominal hysterectomy with bilateral salpingo-oophorectomy with omentectomy. Right ovary showed marked treatment response, however metastatic deposits were seen in the omentum.
Source of Funding
None.
Conflict of Interest
None.
References
- LA Torre, B Trabert, CE Desantis, KD Miller, G Samimi, CD Runowicz. Ovarian cancer statististics. CA Cancer J Clin 2018. [Google Scholar]
- RC Bast, B Hennessy, GB Mills. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009. [Google Scholar]
- SS Buys, E Patridge, A Black, CC Johnson, L Lamerato, C Isaacs. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized control trial. JAMA 2011. [Google Scholar]
- Y Iwagoi, T Motohara, S Hwang, K Fujimoto, T Ikeda, H Katabuchi. Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III-IV epithelial ovarian cancer. Int J Clin Oncol 2021. [Google Scholar]
- T Motohara, H Katabuchi. Ovarian cancer stemness: biological and clinical implications for metastasis and chemotherapy resistance. Cancer 2019. [Google Scholar]
- DD Bowtell, S Bohm, AA Ahmed, PJ Aspuria, RC Bast Jr, V Beral. Rethinking ovarian cancer II: reducing mortality from high grade serous ovarian cancer. Nat Rev Cancer 2015. [Google Scholar]
- M Xiojing. The omentum, a niche for premetastatic ovarian cancer. J Exp Med 2020. [Google Scholar] [Crossref]
- SA Gerber, VY Rybalko, CE Bigelow, TH Foster, JG Ferlinger. Preferential attachment of peritoneal tumor metastasis to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 2006. [Google Scholar]
- JR Moreno, JE Moyron-Quiroz, DM Carragher, L Hartson, A Moquin, TD Randall. Omental milky spots develop in the absence of lymphoid tissue inducer cells and support B and T cell responses to peritoneal antigens. Immunity 2009. [Google Scholar]
- SB Coburn, F Bray, ME Sherman, B Trabert. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J 2017. [Google Scholar]
- JA Gubbels, N Claussen, AK Kapur, JP Connor, MS Patankar. The detection, treatment and biology of epithelial ovarian cancer. J Ovarian Res 2010. [Google Scholar] [Crossref]
- . ACS 2016 Cancer Facts and Figures 2016 American Cancer Society and Journal. 2016. [Google Scholar]
- T Ohsuga, K Yamaguchi, A Kido, R Murakami, K Abiko, J Hamanishi. Distinctive preoperative clinical features predict four histopathological subtypes of high grade serous carcinoma of the ovary, fallopian tube and peritoneum. BMC Cancer 2017. [Google Scholar] [Crossref]
- . Cancer Genome Atlas research Network. Integrated genome analysis of ovarian carcinoma. Nature 2011. [Google Scholar]
- RG Verhaak, P Tamayo, JY Yang, D Hubbard, H Zhang, CJ Creigton. Prognostically relevant gene signatures of high grade serous carcinoma. J Clin Invest 2013. [Google Scholar]
- KM Nieman, HA Kennay, CV Penicka, A Ladanyi, R Buell-Gutbrod, MR Zillhardt. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011. [Google Scholar]
- JS Berek, ST Kehoe, L Kumar, M Friedlander. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2018. [Google Scholar]
- . . National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. National Comprehensive Cancer Network 2017. [Google Scholar]
- S Komiyama, H Katabuchi, M Mikami. Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer. Int J Clin Oncol 2016. [Google Scholar]
- A Ben Arie, L Mcnally, DS Kapp. The omentum and omentectomy in epithelial ovarian cancer: a reappraisal. Part I-omental function and history of omentectomy. Gynecol Oncol 2013. [Google Scholar]
- AB Arie, L Mcnally, DS Kapp. The omentum and omentectomy in epithelial ovarian cancer: a reappraisal: part II-the role of omentectomy in the staging and treatment of apparent early stage epithelial ovarian cancer. Gynecol Oncol 2013. [Google Scholar]